A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma.

Trial Profile

A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Encorafenib (Primary)
  • Indications Colorectal cancer; Malignant melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Array BioPharma
  • Most Recent Events

    • 21 Aug 2017 Planned End Date changed from 31 Jul 2017 to 31 Jul 2018.
    • 28 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 13 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top